Advent Life Sciences’ €215 Million Fundraising

Macfarlanes has advised Advent Life Sciences on the transaction.

Advent Life Sciences raised two new life sciences-focused funds, Advent Life Sciences Fund III and the Advent-Harrington Impact Fund, which have closed with approximately €215m of investor commitments.

Investment commitments came from independent financial investors including international funds-of-funds, research foundations and family offices.

The funds will continue Advent Life Sciences’ investment strategy of identifying and backing high-impact, high-potential innovations that can deliver important new medicines for unmet medical needs.

The Macfarlanes team for this matter was led by investment management partner Chris Good (Picture) with assistance from solicitors Sandeesh Shah and Catherine Born. Tax and reward expertise was provided by partner James McCredie and solicitor Joe Maughan. 

Involved fees earner: Catherine Born – Macfarlanes LLP; Christopher Good – Macfarlanes LLP; Joe Maughan – Macfarlanes LLP; James McCredie – Macfarlanes LLP; Sandeesh Shah – Macfarlanes LLP;

Law Firms: Macfarlanes LLP;

Clients: Advent Life Sciences;

Author: Federica Tiefenthaler